{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:22:34Z","timestamp":1761862954218},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thoracic Surgery Clinics"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.thorsurg.2010.08.004","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T09:40:17Z","timestamp":1289382017000},"page":"115-123","source":"Crossref","is-referenced-by-count":6,"title":["Targeted Therapies for Thymic Malignancies"],"prefix":"10.1016","volume":"21","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma: a focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib2","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart","first-page":"146","author":"WHO Histological Classification of Tumours of the Thymus","year":"2004"},{"issue":"11","key":"10.1016\/j.thorsurg.2010.08.004_bib3","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib4","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2003.11.021","article-title":"Thymic carcinoma: state of the art review","volume":"59","author":"Eng","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"7171","key":"10.1016\/j.thorsurg.2010.08.004_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nature06358","article-title":"Characterizing the cancer genome in lung adenocarcinoma","volume":"450","author":"Weir","year":"2007","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.thorsurg.2010.08.004_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/PAS.0b013e31815cb162","article-title":"Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis","volume":"32","author":"Motoi","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"7216","key":"10.1016\/j.thorsurg.2010.08.004_bib9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"5578","key":"10.1016\/j.thorsurg.2010.08.004_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib11","unstructured":"Pao W, Girard N. New driver mutations in non-small cell lung cancer. Lancet Oncol, in press."},{"issue":"22","key":"10.1016\/j.thorsurg.2010.08.004_bib12","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hoc.2008.03.007","article-title":"Molecular pathology of thymic epithelial neoplasms","volume":"22","author":"Kuhn","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"issue":"25","key":"10.1016\/j.thorsurg.2010.08.004_bib14","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.thorsurg.2010.08.004_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"issue":"34","key":"10.1016\/j.thorsurg.2010.08.004_bib16","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","article-title":"Dasatinib induces a response in malignant thymoma","volume":"24","author":"Chuah","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.thorsurg.2010.08.004_bib17","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2010.08.004_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.thorsurg.2010.08.004_bib19","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.thorsurg.2010.08.004_bib20","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.thorsurg.2010.08.004_bib21","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1101\/gad.1417406","article-title":"Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors","volume":"20","author":"Politi","year":"2006","journal-title":"Genes Dev"},{"issue":"9496","key":"10.1016\/j.thorsurg.2010.08.004_bib22","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib23","first-page":"27","article-title":"Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin\/paclitaxel (C\/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS) [abstract 8006]","author":"Fukuoka","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.thorsurg.2010.08.004_bib24","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.thorsurg.2010.08.004_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9674","key":"10.1016\/j.thorsurg.2010.08.004_bib26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.thorsurg.2010.08.004_bib27","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","article-title":"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer","volume":"27","author":"Laurent-Puig","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.thorsurg.2010.08.004_bib28","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.thorsurg.2010.08.004_bib29","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1101\/gad.947701","article-title":"Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes","volume":"15","author":"Fisher","year":"2001","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib30","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2559.1993.tb01181.x","article-title":"Expression of epidermal and nerve growth factor receptors in human thymus and thymomas","volume":"23","author":"Pescarmona","year":"1993","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.thorsurg.2010.08.004_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jcp.48.5.447","article-title":"Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen","volume":"48","author":"Gilhus","year":"1995","journal-title":"J\u00a0Clin Pathol"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.thorsurg.2010.08.004_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2010.08.004_bib35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","article-title":"Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas","volume":"248","author":"Meister","year":"2007","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.thorsurg.2010.08.004_bib37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JTO.0b013e3181d86a30","volume":"5","author":"Aisner","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2010.08.004_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00595-003-2722-0","article-title":"Elevated serum epidermal growth factor receptor level in stage IV thymoma","volume":"34","author":"Sasaki","year":"2004","journal-title":"Surg Today"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib40","first-page":"23","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies [abstract 7068]","author":"Kurup","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2010.08.004_bib41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutations","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.thorsurg.2010.08.004_bib42","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-04-1981","article-title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer","volume":"11","author":"Chou","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.thorsurg.2010.08.004_bib43","first-page":"1621","article-title":"Aberrant methylation: common in thymic carcinomas, rare in thymomas","volume":"14","author":"Suzuki","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A\u00a0phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma [abstract 19087]","volume":"26","author":"Bedano","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"issue":"5","key":"10.1016\/j.thorsurg.2010.08.004_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-006-0219-4","article-title":"Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells","volume":"58","author":"Qin","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(90)90302-U","article-title":"Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor","volume":"63","author":"Zsebo","year":"1990","journal-title":"Cell"},{"issue":"5350","key":"10.1016\/j.thorsurg.2010.08.004_bib48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.thorsurg.2010.08.004_bib49","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"29","key":"10.1016\/j.thorsurg.2010.08.004_bib50","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"33","key":"10.1016\/j.thorsurg.2010.08.004_bib51","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib52","doi-asserted-by":"crossref","unstructured":"Pan CC, Chen PC, Chiang H.KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202(3):375\u201381.","DOI":"10.1002\/path.1514"},{"issue":"4","key":"10.1016\/j.thorsurg.2010.08.004_bib53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.thorsurg.2010.08.004_bib56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.thorsurg.2010.08.004_bib57","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"23","key":"10.1016\/j.thorsurg.2010.08.004_bib58","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2010.08.004_bib59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.22681","article-title":"L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition","volume":"121","author":"Antonescu","year":"2007","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.thorsurg.2010.08.004_bib60","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-07-0484","article-title":"Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor","volume":"13","author":"Guo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma [abstract 8116]","volume":"26","author":"Salter","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2010.08.004_bib62","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Str\u00f6bel","year":"2010","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.thorsurg.2010.08.004_bib63","doi-asserted-by":"crossref","first-page":"e7273","DOI":"10.1371\/journal.pone.0007273","article-title":"High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)","volume":"4","author":"Gong","year":"2009","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.thorsurg.2010.08.004_bib64","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1200\/JCO.2009.24.6611","article-title":"Insulin-like growth factor receptor 1 (igf1r) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression","volume":"28","author":"Dziadziuszko","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2010.08.004_bib65","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/annonc\/mdn727","article-title":"High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients","volume":"20","author":"Ludovini","year":"2009","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.thorsurg.2010.08.004_bib66","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1677\/erc.1.00799","article-title":"Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells","volume":"11","author":"Jones","year":"2004","journal-title":"Endocr Relat Cancer"},{"issue":"20","key":"10.1016\/j.thorsurg.2010.08.004_bib67","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.thorsurg.2010.08.004_bib68","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1158\/0008-5472.CAN-08-1712","article-title":"Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody","volume":"68","author":"Cao","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib69","first-page":"200","article-title":"Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling","volume":"62","author":"Chakravarti","year":"2002","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.thorsurg.2010.08.004_bib70","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib71","first-page":"25","article-title":"Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC) [abstract 7506]","author":"Karp","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib72","first-page":"25","article-title":"Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors [abstract 3586]","author":"Haluska","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.thorsurg.2010.08.004_bib73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.thorsurg.2010.08.004_bib74","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A\u00a0randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.thorsurg.2010.08.004_bib75","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib76","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"issue":"3","key":"10.1016\/j.thorsurg.2010.08.004_bib77","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"11","key":"10.1016\/j.thorsurg.2010.08.004_bib78","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"key":"10.1016\/j.thorsurg.2010.08.004_bib79","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3599","article-title":"A\u00a0phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results [abstract 3599]","volume":"26","author":"Isambert","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.thorsurg.2010.08.004_bib80","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/02841860802495362","article-title":"Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma","volume":"48","author":"Azad","year":"2009","journal-title":"Acta Oncol"},{"issue":"16","key":"10.1016\/j.thorsurg.2010.08.004_bib81","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.thorsurg.2010.08.004_bib82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00194697","article-title":"Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21","volume":"426","author":"Hayashi","year":"1995","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.thorsurg.2010.08.004_bib83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2559.2003.01663.x","article-title":"Expression of apoptosis-related markers and HER-2\/neu in thymic epithelial tumours","volume":"43","author":"Pan","year":"2003","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.thorsurg.2010.08.004_bib84","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<639::AID-IJC5>3.0.CO;2-Y","article-title":"p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma","volume":"73","author":"Hirabayashi","year":"1997","journal-title":"Int J Cancer"}],"container-title":["Thoracic Surgery Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412710001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412710001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T05:10:08Z","timestamp":1559797808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547412710001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S1547412710001313"],"URL":"https:\/\/doi.org\/10.1016\/j.thorsurg.2010.08.004","relation":{},"ISSN":["1547-4127"],"issn-type":[{"value":"1547-4127","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}